Posts Tagged ‘FDA’
FDA approves nivolumab for adjuvant treatment of urothelial carcinoma
FDA approves nivolumab for adjuvant treatment of urothelial carcinoma On August 19, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Co.) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection. This is the first FDA approval for adjuvant treatment of…
Read MoreFDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors
FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment…
Read More